<div id="readability-page-1"><div>HONG KONG, May 15, 2026 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) announced that on 14 May 2026, based on strong confidence in the company's future prospects and long-term development, Mr. Wei Fu, a non-executive Director, the honorary chairman of the Board and a substantial shareholder of the company, purchased 660,000 ordinary shares of the company on the open-market for a total consideration of approximately HK$20.7 million, representing an average price of approximately HK$31.25 per Share. Mr. Wei Fu pointed out that he does not rule out the possibility of further increasing his shareholdings in the company when appropriate.This marks Mr. Wei Fu's second share purchase in Everest Medicines in 2026. Previously, on March 27, he acquired 860,000 shares of Everest Medicines at an average price of approximately HK$38.12 per share, for a total consideration of approximately HK$32.7 million.Mr. Wei Fu's consecutive share purchases within the year reflect his firm confidence in both Everest Medicines' strategic direction and operational achievements. At the end of 2025, Everest Medicines unveiled its 2030 strategy, which clearly adopts a dual-engine approach driven by both business development collaborations and in-house R&amp;D. By 2030, the company aims to achieve revenue exceeding RMB15 billion and expand its commercialized product portfolio to more than 20 products, while continuing to focus on high-growth therapeutic areas including nephrology, cardiovascular and metabolic diseases. In December 2025, the management team and substantial shareholders collectively increased their shareholdings in the market, signaling long-term confidence in the company's development.On the operational front, Everest Medicines reported total revenue of RMB1.707 billion for the full year of 2025, representing a year-over-year increase of 142%. The company also achieved annual profitability for the first time on a non-IFRS basis, recording a profit of RMB187 million, while operating cash flow turned positive in the fourth quarter. Sales revenue of NEFECON' reached RMB1.443 billion, representing growth of more than 300% year-over-year, making it the first non-oncology innovative drug in China to exceed RMB1 billion in annual sales in its first year of inclusion in the National Reimbursement Drug List (NRDL). Meanwhile, XERAVA' achieved sales revenue of RMB262 million, with in-hospital sales increasing by 44% year-over-year. These results further validate the company's strengthening commercialization capabilities and continued execution momentum.The management team's collective shareholding increases and Mr. Fu's consecutive share purchases in 2026 demonstrated strong confidence in the Company's long-term prospects. Supported by strong operational execution and strategic implementation, Everest Medicines' medium- to long-term growth trajectory is becoming increasingly clear.Source: Everest Medicines LimitedCopyright 2026 ACN Newswire . All rights reserved.</div></div>

01952

588130

159992

On May 14, 2026, Wei Fu, a substantial shareholder of Everest Medicines, purchased 660,000 shares for approximately HK$20.7 million, marking his second acquisition this year. His previous purchase was on March 27, acquiring 860,000 shares. These actions reflect his confidence in the company's strategic direction and operational achievements, as Everest aims for over RMB15 billion in revenue by 2030. The company reported a 142% revenue increase in 2025, achieving profitability for the first time and strong sales in its innovative drugs.

Asian Corporate Newswire

EVEREST MED

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CNI HK Connect Innovative Drugs ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence